Synonyms: (2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol; (R)-5'-phenyl-7-deazaadenosine; 6-amino-9-[(R)-5'-phenyl(ribofuranosyl)]-7-deazapurine; LLY 283; LLY283
Molecular Formula: C17H18N4O4
Molecular Weight: 342.35
Linear Structural Formula: C17H18N4O4
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: LLY-283 is a potent and selective SAM-competitive PRMT5 inhibitor (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) with greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. LLY-283 inhibits Smith (Sm) antigen SmBB' methylation in MCF7 cells (IC50 = 25 nM; 3 days) and affects MDM4 splicing in A375 cells (IC50 = 40 nM; 3 days). The diastereomer LLY-284 is less potent in the biochemical assay and is an ideal control compound for cellular studies. For characterization details of LLY-283, please visit the LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.LLY-284 is the negative control for the active probe, LLY-283. LLY-284 is available from Sigma. To learn more about and purchase LLY-284, click here.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc